Spots Global Cancer Trial Database for cutaneous
Every month we try and update this database with for cutaneous cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study of ONTAK® to Treat Cutaneous T-Cell Lymphoma (CTCL) | NCT00211198 | Lymphoma, T-Cel... | ONTAK (denileuk... | 18 Years - | Eisai Inc. | |
| Palliative Treatment of Ulcerated Cutaneous Metastases: Trial Between Electrochemotherapy and Radiotherapy | NCT00918593 | Ulcerated Cutan... | Electrochemothe... Radiotherapy Bleomycin | 18 Years - | Copenhagen University Hospital at Herlev | |
| Phase I Oncovir Poly IC:LC and NY-ESO-1/gp100 | NCT01008527 | Melanoma | CP 870,893 Peptides Oncovir poly IC... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Pilot Study of Infrared Imaging of Cutaneous Melanoma | NCT00937690 | Melanoma | 18 Years - | University of Virginia | ||
| Capecitabine or 5-FU With Pegylated Interferon Alpha-2b in Unresectable/Metastatic Cutaneous Squamous Cell Carcinoma | NCT02218164 | Squamous Cell C... Carcinoma, Squa... | Pegylated Inter... Capecitabine 5-FU | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| A Safety, Efficacy and Pharmacokinetics Study of CD11301 for the Treatment of Cutaneous T-Cell Lymphoma (CTCL) | NCT03292406 | Cutaneous T Cel... | Placebo CD11301 0.03% CD11301 0.06% | 18 Years - | Galderma R&D | |
| Efficacy and Safety Study of REM-001 Photodynamic Therapy for Treatment of Cutaneous Metastatic Breast Cancer (CMBC) | NCT05374915 | Cutaneous Breas... | REM-001 photody... | 18 Years - | Kintara Therapeutics, Inc. | |
| A Study of Ultrasonography With Elastography in Skin Neoplasms | NCT01259037 | Benign and Mali... | 18 Years - 99 Years | Wayne State University | ||
| Study Using the MedPulser Electroporation System With Bleomycin to Treat Cutaneous and Subcutaneous Cancer | NCT00198276 | Cancer | MedPulser Elect... | 18 Years - | Inovio Pharmaceuticals | |
| Capecitabine or 5-FU With Pegylated Interferon Alpha-2b in Unresectable/Metastatic Cutaneous Squamous Cell Carcinoma | NCT02218164 | Squamous Cell C... Carcinoma, Squa... | Pegylated Inter... Capecitabine 5-FU | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Study of T-VEC in Locally Advanced Cutaneous Angiosarcoma | NCT03921073 | Angiosarcoma of... | T-VEC | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Chemotherapy-induced Peripheral Neuropathy (CIPN) on Motor and Sensory Function | NCT04799080 | Cancer Chemotherapy-in... Chemotherapeuti... Breast Cancer Breast Neoplasm... Colon Neoplasm Colo-rectal Can... | 18 Years - 85 Years | Izmir Bakircay University | ||
| Chemotherapy-induced Peripheral Neuropathy (CIPN) on Motor and Sensory Function | NCT04799080 | Cancer Chemotherapy-in... Chemotherapeuti... Breast Cancer Breast Neoplasm... Colon Neoplasm Colo-rectal Can... | 18 Years - 85 Years | Izmir Bakircay University | ||
| Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell Carcinoma | NCT03071406 | Merkel Cell Car... Skin Cancer | Nivolumab Ipilimumab Stereotactic Bo... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell Carcinoma | NCT03071406 | Merkel Cell Car... Skin Cancer | Nivolumab Ipilimumab Stereotactic Bo... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Phase I Dose-finding and Preliminary Efficacy Study of the Istodax® in Combination With Doxil® for the Treatment of Adults With Relapsed or Refractory Cutaneous T-cell Lymphoma | NCT01902225 | Lymphoma T-Cell Lymphoma Cutaneous Lymph... | Istodax Doxil | 18 Years - | University of California, San Francisco | |
| A Safety, Efficacy and Pharmacokinetics Study of CD11301 for the Treatment of Cutaneous T-Cell Lymphoma (CTCL) | NCT03292406 | Cutaneous T Cel... | Placebo CD11301 0.03% CD11301 0.06% | 18 Years - | Galderma R&D | |
| Chemotherapy-induced Peripheral Neuropathy (CIPN) on Motor and Sensory Function | NCT04799080 | Cancer Chemotherapy-in... Chemotherapeuti... Breast Cancer Breast Neoplasm... Colon Neoplasm Colo-rectal Can... | 18 Years - 85 Years | Izmir Bakircay University | ||
| Phase I Dose-finding and Preliminary Efficacy Study of the Istodax® in Combination With Doxil® for the Treatment of Adults With Relapsed or Refractory Cutaneous T-cell Lymphoma | NCT01902225 | Lymphoma T-Cell Lymphoma Cutaneous Lymph... | Istodax Doxil | 18 Years - | University of California, San Francisco | |
| Pilot Study of Infrared Imaging of Cutaneous Melanoma | NCT00937690 | Melanoma | 18 Years - | University of Virginia |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
